Ventricular FibrillationEuroEcoNCT00776087
European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco)
A study testing Home Monitoring provided by Biotronik ICD and CRT-D devices and No Home Monitoring in people with Ventricular Fibrillation and Tachycardia, Ventricular, run by Biotronik SE & Co. KG at 17 sites in 6 countries.
Trial summary
BIOTRONIK Home Monitoring (HM) service enables the doctors to safely follow up (FU) their ICD and CRT-D patients in a remote fashion, with fewer in-clinic consultations. This may result in a more efficient FU and cost-savings for the health care payer. The EuroEco study: 1. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ventricular Fibrillation, Tachycardia, Ventricular, Ventricular Flutter
- What is being tested?
- Home Monitoring provided by Biotronik ICD and CRT-D devices and No Home Monitoring
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 409 participants
- Where
- 17 sitesin 6 countries
- Study dates
- 17 Oct 2008to 27 Oct 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
ICD Patient Population - Inclusion Criteria
- Indication for 1-/2- chamber ICD implantation, including replacement indication
- Patient is willing and able to comply with the clinical investigation plan and has provided written informed consent
ICD Patient Population - Exclusion Criteria
- Patients with contraindication to ICD implantation
- Patients with indication for cardiac resynchronization (CRT)
- Minors and pregnant women
- Patients participating in another study
CRT-D Patient Population - Inclusion Criteria
- Patients with indication for de novo CRT-D implantation according to current guidelines
- Patient is willing and able to comply with the clinical investigation plan and has provided written informed consent
CRT-D Patient Population - Exclusion Criteria
- Patients who had a cardiac device implanted before (upgrade, device replacement)
- Life expectancy less than 12 months
- Planned heart transplantation
- NYHA IV
- Minors < 18 years
- Pregnant and breast-feeding women
- Participation in another clinical study
Trial locations and contacts
17 sites in 6 countries.
17 sites in 6 countries
Belgium4 sites
Heart Rhythm Management Institute, Free University of Brussels
Brussels
Ziekenhuis Oost Limburg, Campus St. Jan
Genk
Jessa Ziekenhuis (Campus Virga Jesse)
Hasselt
ZU Gasthuisberg
Leuven
Germany4 sites
Helios Klinikum Aue
Aue, 08280
Charité Berlin Campus Mitte
Berlin, 10117
Städt. Klinikum St. Georg gGmbH
Leipzig, 04129
Herzzentrum Leipzig, Abteilung Rhythmologie
Leipzig
Spain4 sites
Hospital Universitario La Paz
La Paz
Hospital Universitario Puerta de Hierro Majadahonda
Madrid
Hospital Ntra.Sra.de la Candelaria
Santa Cruz de Tenerife
Arrythmia Unit, Complejo Hospitalario de Vigo (Hospital Xeral)
Vigo
United Kingdom3 sites
Cardiology, Aberdeen Royal Infirmary
Aberdeen
Cardiology, St. Peters Hospital/St. George's
Chertsey
Cardiology; Raigmore Hospital
Inverness
About this study
BIOTRONIK Home Monitoring (HM) service enables the doctors to safely follow up (FU) their ICD and CRT-D patients in a remote fashion, with fewer in-clinic consultations. This may result in a more efficient FU and cost-savings for the health care payer.
The EuroEco study:
- Outlines a new HM-based FU model for the ICD and CRT-D patients that combines in-clinic consultations and regular check ups of the patient/ICD/CRT-D data received through the HM service.
- Compares the direct costs for physicians and clinics for the HM-based FU of ICD and CRT-D patients versus the traditional FU.
- Compares the indicators of patients' safety between the two FU models.
Read the detailed description
The EuroEco is a prospective, international, randomized study aimed at assessing the economic effects of BIOTRONIK Home Monitoring (HM) technology as compared with traditional follow up (FU) of ICD and CRT-D patients from two perspectives: 1) the cost-effectiveness for the payer of health care, and 2) the economic impact on the physician, hospital and patient. The study outlines a new model for the FU of ICD-and CRT-D patients based on a combination of in-clinic consultations and regular check ups of the patient data received through the HM service.
About 312 patients with an indication for ICD therapy and 104 patients with an indication for de novo CRT-D implantation should be enrolled. All patients will be implanted with BIOTRONIK ICD or CRT-D devices from the Lumax families and randomized (1:1) to the traditional, or to HM-based FU model. Traditional FU will be performed according to the local clinical practice. Patients in the HM study arm will first undergo local clinical FU routine until the first in-clinic visit after patient discharge. Thereafter routine in-clinic FUs are scheduled at 12 and 24 months. Three HM data checks should be carried out during each 12-month interval, to assess the patient/ICD/CRT-D status remotely.
In both (HM and no HM) groups, additional in-hospital FU may be scheduled any time the patients reports symptoms which are presumed to be cardiovascular symptoms. In the HM group, additional in-clinic FU may also be scheduled as a result of specific HM findings.
The following FU-related activities were accounted for: in-clinic consultations, patients contact, discussion with colleague physician, nurse or technician and arranging in clinic consultation. In HM patients, two additional HM-related FU activities were taken into account: 1) checking the website of BIOTRONIK HM Service Center, and 2) checking HM-related emails and faxes (provided by BIOTRONIK HM Service Center)..
Several tools were made available to document the time that physicians, nurses and technicians spend with these FU activities without disrupting their clinical routine much:
- designated case report forms
- a web-based time measurements software.
A user manual for time measurements was handed out to physicians, nurses and technicians to recommend which tool should be used in which clinical situation. The average time per patient followed according to the traditional FU model and the average time per patient followed by the HM-based FU model will be calculated for each of the three health care professionals considered (physicians, nurses and technicians). The difference in costs between the traditional and the HM-based FU will be assessed for statistical significance.
This trial may provide data warranting a change in the guidelines for the use of ICD and CRT-D devices featuring HM function, in that HM may justify a prolongation of the time interval between statutory routine in-clinic FU visits. Coupled with the fact that the information provided by HM helps physicians to recognize some otherwise unsuspected needs for additional FU visits, this may ultimately result in better and more cost-effective health care for all parts involved (patients, providers and payers).
- Being tested
- Home Monitoring provided by Biotronik ICD and CRT-D devices, No Home Monitoring
- Keywords
- Medical costs, Telemonitoring, Implantable cardioverter-defibrillator
- Medical subject headings
- Ventricular Fibrillation, Tachycardia, Ventricular, Ventricular Flutter
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Home Monitoring provided by Biotronik ICD and CRT-D devicesDevice
Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
No Home MonitoringDevice
Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
| Study group | Role | What they receive |
|---|---|---|
| 1 = Home Monitoring | Experimental | Remote monitoring of ICD and CRT-D function and patient status Receives: Device: Home Monitoring provided by Biotronik ICD and CRT-D devices |
| 2 = No Home Monitoring | Active comparator | Home Monitoring option is switched off Receives: Device: No Home Monitoring |
What is being measured
The primary outcome is the main question the study is designed to answer.
Euro spent to follow up ICD and CRT-D patients
Measured: 26 months
Secondary outcomes (7)
Average number of in-hospital follow-up visits per patient
Measured: 26 months
Time to first in-hospital follow-up visit beyond the first post-implantation visit
Measured: 12 months
Effective financial impact on hospitals / physicians
Measured: 26 months
Proportion of in-hospital consultations with relevant findings (i.e. necessitating changes in medical therapy, device programming or re-hospitalisations/ interventions)
Measured: 26 months
Proportion of patients with HM-triggered interventions that, without remote monitoring, would have first been discovered at a subsequent scheduled follow-up
Measured: 26 months
Incidence of inappropriate ICD shocks
Measured: 26 months
Changes in quality-of-life (SF-36) from baseline to the 12- and to 24-month follow-up visits
Measured: 26 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2008 (estimated)
- Study start17 Oct 2008
- Primary completion21 Jul 2016
- Study completion27 Oct 2016
Why it stopped: it is unethical to continue a study with deactivation of HM in the control arm although a reduced risk of all-cause death has been shown in previous trials
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ventricular FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized prospective multicenter international clinical trial
- Masking
- None (open label)
- Enrolment
- 409 participants (actual)
Sponsor and investigators
- Lead sponsor
- Biotronik SE & Co. KG
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Hein Heidbüchel, Prof. Dr., Study chair, ZU Gasthuisberg, Leuven, Belgium
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00776087
- Sponsor's protocol ID
- HS043
- Acronym
- EuroEco
- Status last verified
- Jun 2017
- First submitted
- 17 Oct 2008
- Last updated
- 2 Jul 2017
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco)
- ClinicalTrials.gov ID
- NCT00776087
- Acronym / sponsor ID
- EuroEco / HS043
- Keywords
- Medical costs, Telemonitoring, Implantable cardioverter-defibrillator
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: it is unethical to continue a study with deactivation of HM in the control arm although a reduced risk of all-cause death has been shown in previous trials
- Enrolment
- 409 participants (actual)
- Lead sponsor
- Biotronik SE & Co. KGIndustry (pharma, biotech, devices)
- Study start
- 17 Oct 2008 (actual)
- Primary completion
- 21 Jul 2016 (actual)
- Study completion
- 27 Oct 2016 (actual)
- First posted
- 20 Oct 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
BIOTRONIK Home Monitoring (HM) service enables the doctors to safely follow up (FU) their ICD and CRT-D patients in a remote fashion, with fewer in-clinic consultations. This may result in a more efficient FU and cost-savings for the health care payer.
The EuroEco study:
- Outlines a new HM-based FU model for the ICD and CRT-D patients that combines in-clinic consultations and regular check ups of the patient/ICD/CRT-D data received through the HM service.
- Compares the direct costs for physicians and clinics for the HM-based FU of ICD and CRT-D patients versus the traditional FU.
- Compares the indicators of patients' safety between the two FU models.
Detailed description
The EuroEco is a prospective, international, randomized study aimed at assessing the economic effects of BIOTRONIK Home Monitoring (HM) technology as compared with traditional follow up (FU) of ICD and CRT-D patients from two perspectives: 1) the cost-effectiveness for the payer of health care, and 2) the economic impact on the physician, hospital and patient. The study outlines a new model for the FU of ICD-and CRT-D patients based on a combination of in-clinic consultations and regular check ups of the patient data received through the HM service.
About 312 patients with an indication for ICD therapy and 104 patients with an indication for de novo CRT-D implantation should be enrolled. All patients will be implanted with BIOTRONIK ICD or CRT-D devices from the Lumax families and randomized (1:1) to the traditional, or to HM-based FU model. Traditional FU will be performed according to the local clinical practice. Patients in the HM study arm will first undergo local clinical FU routine until the first in-clinic visit after patient discharge. Thereafter routine in-clinic FUs are scheduled at 12 and 24 months. Three HM data checks should be carried out during each 12-month interval, to assess the patient/ICD/CRT-D status remotely.
In both (HM and no HM) groups, additional in-hospital FU may be scheduled any time the patients reports symptoms which are presumed to be cardiovascular symptoms. In the HM group, additional in-clinic FU may also be scheduled as a result of specific HM findings.
The following FU-related activities were accounted for: in-clinic consultations, patients contact, discussion with colleague physician, nurse or technician and arranging in clinic consultation. In HM patients, two additional HM-related FU activities were taken into account: 1) checking the website of BIOTRONIK HM Service Center, and 2) checking HM-related emails and faxes (provided by BIOTRONIK HM Service Center)..
Several tools were made available to document the time that physicians, nurses and technicians spend with these FU activities without disrupting their clinical routine much:
- designated case report forms
- a web-based time measurements software.
A user manual for time measurements was handed out to physicians, nurses and technicians to recommend which tool should be used in which clinical situation. The average time per patient followed according to the traditional FU model and the average time per patient followed by the HM-based FU model will be calculated for each of the three health care professionals considered (physicians, nurses and technicians). The difference in costs between the traditional and the HM-based FU will be assessed for statistical significance.
This trial may provide data warranting a change in the guidelines for the use of ICD and CRT-D devices featuring HM function, in that HM may justify a prolongation of the time interval between statutory routine in-clinic FU visits. Coupled with the fact that the information provided by HM helps physicians to recognize some otherwise unsuspected needs for additional FU visits, this may ultimately result in better and more cost-effective health care for all parts involved (patients, providers and payers).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Randomized prospective multicenter international clinical trial
| Arm | Type | Receives |
|---|---|---|
| 1 = Home Monitoring | Experimental | Device: Home Monitoring provided by Biotronik ICD and CRT-D devicesRemote monitoring of ICD and CRT-D function and patient status |
| 2 = No Home Monitoring | Active comparator | Device: No Home MonitoringHome Monitoring option is switched off |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Home Monitoring provided by Biotronik ICD and CRT-D devicesRemote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety | Device | 1 = Home Monitoring |
| No Home MonitoringHome Monitoring option is switched off (in the same kind of devices as used in the other study arm). | Device | 2 = No Home Monitoring |
Primary outcome
Euro spent to follow up ICD and CRT-D patients
Time frame: 26 months
7 secondary outcomes
Average number of in-hospital follow-up visits per patient
Time frame: 26 months
Time to first in-hospital follow-up visit beyond the first post-implantation visit
Time frame: 12 months
Effective financial impact on hospitals / physicians
Time frame: 26 months
Proportion of in-hospital consultations with relevant findings (i.e. necessitating changes in medical therapy, device programming or re-hospitalisations/ interventions)
Time frame: 26 months
Proportion of patients with HM-triggered interventions that, without remote monitoring, would have first been discovered at a subsequent scheduled follow-up
Time frame: 26 months
Incidence of inappropriate ICD shocks
Time frame: 26 months
Changes in quality-of-life (SF-36) from baseline to the 12- and to 24-month follow-up visits
Time frame: 26 months
Results and safety
The study was stopped early (reason given: it is unethical to continue a study with deactivation of HM in the control arm although a reduced risk of all-cause death has been shown in previous trials). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2017.
- Individual participant dataSharing planned: No
Related trials for Ventricular Fibrillation
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Recruiting
A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter
Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation
RecruitingObservational study
AI-Based Cardiac Analysis Using 12-Lead and 1-Lead ECG
Heart Failure, Atrial Fibrillation (AF)
RecruitingObservational study
The Multicenter Cardiology Monitoring Platform Registry
Heart Failure, Cardiomyopathies
Not yet recruiting
Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan
Atrial Fibrillation (AF), Atrial Flutter
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hein Heidbüchel, Prof. Dr. study chair
ZU Gasthuisberg, Leuven, Belgium
17 sites in 6 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Home Monitoring provided by Biotronik ICD and CRT-D devices and No Home Monitoring in people with Ventricular Fibrillation and Tachycardia, Ventricular, run by Biotronik SE & Co. KG at 17 sites in 6 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 2 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 17 sites in Belgium, Germany, Spain, United Kingdom, Finland and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: it is unethical to continue a study with deactivation of HM in the control arm although a reduced risk of all-cause death has been shown in previous trials). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Euro spent to follow up ICD and CRT-D patients (time frame: 26 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2017; AzTrials last refreshed its copy on 8 Nov 2026.